WuXi Biologics completes Vaccines Ireland facility asset transaction

WuXi Biologics (Cayman) Inc. (HKEX:2269) announced the completion of its asset transaction related to the Vaccines Ireland Facility, effective March 31, 2025. The total consideration for the transaction is US$499.63 million, which includes a payment of US$407.00 million to the vendor, an escrow amount of US$30.00 million, and the offset of a US$62.63 million advance. Additionally, the company is changing its Hong Kong principal place of business address, effective April 1, 2025, to 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. This announcement supplements the company's prior disclosure on the matter dated January 6, 2025.